World Heart Federation Cholesterol Roadmap 2022

Kausik K. Ray; Brian A. Ference; Tania Séverin; Dirk Blom; Stephen J. Nicholls; Mariko H. Shiba; Wael Almahmeed; Rodrigo Alonso; Magdalena Daccord; Marat Ezhov; Rosa Fernández Olmo; Piotr Jankowski; Fernando Lanas; Roopa Mehta; Raman Puri; Nathan D. Wong; David Wood; Dong Zhao; Samuel S. Gidding; Salim S. Virani; Donald Lloyd-Jones; Fausto Pinto; Pablo Perel; Raul D. Santos

doi:10.5334/gh.1154

World Heart Federation Cholesterol Roadmap 2022

Volume 17 (2022): Issue 1

By: Kausik K. Ray , Brian A. Ference, Tania Séverin, Dirk Blom, Stephen J. Nicholls, Mariko H. Shiba, Wael Almahmeed, Rodrigo Alonso, Magdalena Daccord, Marat Ezhov, Rosa Fernández Olmo, Piotr Jankowski, Fernando Lanas, Roopa Mehta, Raman Puri, Nathan D. Wong, David Wood, Dong Zhao, Samuel S. Gidding, Salim S. Virani, Donald Lloyd-Jones, Fausto Pinto, Pablo Perel and Raul D. Santos

Open Access

|Oct 2022

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25): 2982–3021. DOI: 10.1016/j.jacc.2020.11.010
Open DOI Search in Google Scholar Back to article
Rittiphairoj T, Reilly A, Reddy CL, Barrenho E, Colombo FRA. The State of Cardiovascular Disease in G20+ countries. Health Systems Innovation Lab, Harvard University; 2022.
Search in Google Scholar Back to article
Nadarajah R, Wu J, Hurdus B, Asma S, Bhatt DL, Biondi-Zoccai G, et al. The collateral damage of COVID-19 to cardiovascular services: A meta-analysis. European Heart Journal; 2022. DOI: 10.1093/eurheartj/ehac227
Open DOI Search in Google Scholar Back to article
NCD Countdown 2030: Efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries. Lancet. 2022; 399(10331): 1266–78. DOI: 10.1016/S0140-6736(21)02347-3
Open DOI Search in Google Scholar Back to article
Murphy A, Faria-Neto JR, Al-Rasadi K, Blom D, Catapano A, Cuevas A, et al. World Heart Federation Cholesterol Roadmap. Glob Heart. 2017; 12(3): 179–97.e5. DOI: 10.1016/j.gheart.2017.03.002
Open DOI Search in Google Scholar Back to article
NCD Risk Factor Collaboration (NCD-RisC). National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: A pooled analysis of 458 population-based studies in Asian and Western countries. Int J Epidemiol. 2020; 49(1): 173–92.
Search in Google Scholar Back to article
Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. Jama. 2009; 302(18): 1993–2000. DOI: 10.1001/jama.2009.1619
Open DOI Search in Google Scholar Back to article
NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020; 582(7810): 73–7.
Search in Google Scholar Back to article
Mark L, Vallejo-Vaz AJ, Reiber I, Paragh G, Kondapally Seshasai SR, Ray KK. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. Atherosclerosis. 2015; 241(1): 62–8. DOI: 10.1016/j.atherosclerosis.2015.04.810
Open DOI Search in Google Scholar Back to article
Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022; 7(3): 250–6. DOI: 10.1001/jamacardio.2021.5083
Open DOI Search in Google Scholar Back to article
Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial. Lancet. 2022; 400(10349): 380–90. DOI: 10.1016/S0140-6736(22)00916-3
Open DOI Search in Google Scholar Back to article
ESC Committee for Practice Guidelines (CPG), Societies ENC. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290: 140–205.
Search in Google Scholar Back to article
Nasir K, Cainzos-Achirica M. Role of coronary artery calcium score in the primary prevention of cardiovascular disease. BMJ. 2021; 373: n776. DOI: 10.1136/bmj.n776
Open DOI Search in Google Scholar Back to article
Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. Jama. 2013; 310(19): 2061–8. DOI: 10.1001/jama.2013.280532
Open DOI Search in Google Scholar Back to article
Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020; 5(5): 540–8. DOI: 10.1001/jamacardio.2020.0013
Open DOI Search in Google Scholar Back to article
Sathiyakumar V, Park J, Golozar A, Lazo M, Quispe R, Guallar E, et al. Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy. Circulation. 2018; 137(1): 10–9. DOI: 10.1161/CIRCULATIONAHA.117.030677
Open DOI Search in Google Scholar Back to article
Sajja A, Park J, Sathiyakumar V, Varghese B, Pallazola VA, Marvel FA, et al. Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels. JAMA Netw Open. 2021; 4(10): e2128817. DOI: 10.1001/jamanetworkopen.2021.28817
Open DOI Search in Google Scholar Back to article
Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society Consensus Statement. In press; 2022. DOI: 10.1093/eurheartj/ehac361
Open DOI Search in Google Scholar Back to article
Jacobs DR, Jr., Woo JG, Sinaiko AR, Daniels SR, Ikonen J, Juonala M, et al. Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events. N Engl J Med. 2022; 386(20): 1877–88. DOI: 10.1056/NEJMoa2109191
Open DOI Search in Google Scholar Back to article
Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation. 2016; 133(2): 187–225. DOI: 10.1161/CIRCULATIONAHA.115.018585
Open DOI Search in Google Scholar Back to article
Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, Garcia-Rios A, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022; 399(10338): 1876–85. DOI: 10.1016/S0140-6736(22)00122-2
Open DOI Search in Google Scholar Back to article
Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020; 5(5): Cd011737. DOI: 10.1002/14651858.CD011737.pub2
Open DOI Search in Google Scholar Back to article
Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009; 63(Suppl 2): S5–21. DOI: 10.1038/sj.ejcn.1602973
Open DOI Search in Google Scholar Back to article
Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, et al. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2021; 144(23): e472–e87. DOI: 10.1161/CIR.0000000000001031
Open DOI Search in Google Scholar Back to article
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 202133; 42(34): 3227–337.
Search in Google Scholar Back to article
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73(24): e285–e350. DOI: 10.1016/j.jacc.2018.11.003
Open DOI Search in Google Scholar Back to article
WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019; 7(10): e1332–e45.
Search in Google Scholar Back to article
Malik S, Zhao Y, Budoff M, Nasir K, Blumenthal RS, Bertoni AG, et al. Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol. 2017; 2(12): 1332–40. DOI: 10.1001/jamacardio.2017.4191
Open DOI Search in Google Scholar Back to article
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–88. DOI: 10.1093/eurheartj/ehz455
Open DOI Search in Google Scholar Back to article
Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study. Circulation. 2022; 145(17): 1324–38. DOI: 10.1161/CIRCULATIONAHA.121.057889
Open DOI Search in Google Scholar Back to article
Gidding SS, Colangelo LA, Nwabuo CC, Lewis CE, Jacobs DR, Schreiner PJ, et al. PDAY risk score predicts cardiovascular events in young adults: the CARDIA study. Eur Heart J. 2022; 43(30): 2892–900. DOI: 10.1093/eurheartj/ehac009
Open DOI Search in Google Scholar Back to article
Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381–91. DOI: 10.1001/jama.2019.14120
Open DOI Search in Google Scholar Back to article
Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012; 60(25): 2631–9. DOI: 10.1016/j.jacc.2012.09.017
Open DOI Search in Google Scholar Back to article
Jousilahti P, Laatikainen T, Peltonen M, Borodulin K, Mannisto S, Jula A, et al. Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study. BMJ. 2016; 352: i721. DOI: 10.1136/bmj.i721
Open DOI Search in Google Scholar Back to article
JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014; 100(Suppl 2): ii1–ii67. DOI: 10.1136/heartjnl-2014-305693
Open DOI Search in Google Scholar Back to article
Joint Committee for Guideline Revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018; 15(1): 1–29.
Search in Google Scholar Back to article
Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012; 366(4): 321–9. DOI: 10.1056/NEJMoa1012848
Open DOI Search in Google Scholar Back to article
Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020; 141(22): 1742–59. DOI: 10.1161/CIRCULATIONAHA.119.044795
Open DOI Search in Google Scholar Back to article
Blom DJ. Familial hypercholesterolemia. South African Family Practice. 2011; 53(1): 11–8. DOI: 10.1080/20786204.2011.10874054
Open DOI Search in Google Scholar Back to article
EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021; 398(10312): 1713–25.
Search in Google Scholar Back to article
Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019; 381(16): 1547–56. DOI: 10.1056/NEJMoa1816454
Open DOI Search in Google Scholar Back to article
Brandts J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, Jones R, Kastelein JJP, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021; 325: 46–56. DOI: 10.1016/j.atherosclerosis.2021.03.042
Open DOI Search in Google Scholar Back to article
Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: A consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016; 4(10): 850–61. DOI: 10.1016/S2213-8587(16)30041-9
Open DOI Search in Google Scholar Back to article
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, et al. Worldwide experience of homozygous familial hypercholesterolaemia: Retrospective cohort study. Lancet. 2022; 399(10326): 719–28. DOI: 10.1016/S0140-6736(21)02001-8
Open DOI Search in Google Scholar Back to article
Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. Jama. 2006; 295(2): 180–9. DOI: 10.1001/jama.295.2.180
Open DOI Search in Google Scholar Back to article
McKay AJ, Gunn LH, Ference BA, Dorresteijn JAN, Berkelmans GFN, Visseren FLJ, et al. Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals. Eur J Prev Cardiol; 2021. DOI: 10.1093/eurjpc/zwab093
Open DOI Search in Google Scholar Back to article
Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, et al. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation. 2016; 134(19): 1419–29. DOI: 10.1161/CIRCULATIONAHA.116.021314
Open DOI Search in Google Scholar Back to article
Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study. Eur J Prev Cardiol. 2021; 28(11): 1279–89. DOI: 10.1093/eurjpc/zwaa047
Open DOI Search in Google Scholar Back to article
Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. European Heart Journal. 2022; 43(18): 1715–27. DOI: 10.1093/eurheartj/ehac056
Open DOI Search in Google Scholar Back to article
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139(25): e1082–e143. DOI: 10.1161/CIR.0000000000000698
Open DOI Search in Google Scholar Back to article
Adler AJ, Prabhakaran D, Bovet P, Kazi DS, Mancia G, Mungal-Singh V, et al. Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. Glob Heart. 2015; 10(2): 111–22. DOI: 10.1016/j.gheart.2015.04.006
Open DOI Search in Google Scholar Back to article
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459–72. DOI: 10.1093/eurheartj/ehx144
Open DOI Search in Google Scholar Back to article
Banach M, Duell PB, Gotto AM, Jr., Laufs U, Leiter LA, Mancini GBJ, et al. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020; 5(10): 1124–35. DOI: 10.1001/jamacardio.2020.2314
Open DOI Search in Google Scholar Back to article
Kumar D, Yasin U, Saghir T, Akbar Sial J, Khatti S, Khan K, et al. Statin induced myalgia on high intensity statin in patients with Acute Coronary Syndrome. European Heart Journal. 2021; 42(Supplement 1). DOI: 10.1093/eurheartj/ehab724.1413
Open DOI Search in Google Scholar Back to article
Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence – Focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018; 39(27): 2526–39. DOI: 10.1093/eurheartj/ehy182
Open DOI Search in Google Scholar Back to article
Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, et al. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol; 2022. DOI: 10.1016/j.jacl.2022.03.001
Open DOI Search in Google Scholar Back to article
De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019; 285: 135–46. DOI: 10.1016/j.atherosclerosis.2019.03.014
Open DOI Search in Google Scholar Back to article
Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008; 337: a2423. DOI: 10.1136/bmj.a2423
Open DOI Search in Google Scholar Back to article
Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016; 67(11): 1278–85. DOI: 10.1016/j.jacc.2016.01.008
Open DOI Search in Google Scholar Back to article
Brandts J, Ray KK. Familial Hypercholesterolemia: JACC Focus Seminar 4/4. J Am Coll Cardiol. 2021; 78(18): 1831–43. DOI: 10.1016/j.jacc.2021.09.004
Open DOI Search in Google Scholar Back to article
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385(9965): 341–50. DOI: 10.1016/S0140-6736(14)61374-X
Open DOI Search in Google Scholar Back to article
Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020; 75(6): 565–74. DOI: 10.1016/j.jacc.2019.12.020
Open DOI Search in Google Scholar Back to article
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020; 383(8): 711–20. DOI: 10.1056/NEJMoa2004215
Open DOI Search in Google Scholar Back to article
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019; 380(1): 11–22. DOI: 10.1056/NEJMoa1812792
Open DOI Search in Google Scholar Back to article
Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos RD, et al. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis; 2022. DOI: 10.1016/j.pcad.2022.01.002
Open DOI Search in Google Scholar Back to article
Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009; 6(3): 229–39. DOI: 10.1038/ncpcardio1456
Open DOI Search in Google Scholar Back to article
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020; 41(44): 4245–55. DOI: 10.1093/eurheartj/ehaa649
Open DOI Search in Google Scholar Back to article
Marcus ME, Manne-Goehler J, Theilmann M, Farzadfar F, Moghaddam SS, Keykhaei M, et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: A cross-sectional study of nationally representative, individual-level data. Lancet Glob Health. 2022; 10(3): e369–e79. DOI: 10.1016/S2214-109X(21)00551-9
Open DOI Search in Google Scholar Back to article
McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. Atherosclerosis. 2018; 275: 434–43. DOI: 10.1016/j.atherosclerosis.2018.05.047
Open DOI Search in Google Scholar Back to article
Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child-Parent Familial Hypercholesterolemia Screening in Primary Care. N Engl J Med. 2016; 375(17): 1628–37. DOI: 10.1056/NEJMoa1602777
Open DOI Search in Google Scholar Back to article
Groselj U, Wiegman A, Gidding SS. Screening in children for familial hypercholesterolaemia: start now. Eur Heart J; 2022. DOI: 10.1093/eurheartj/ehac224
Open DOI Search in Google Scholar Back to article
FH Europe. FH Europe Post-technical meeting: Statement on FH Paediatric Screening 2021 [cited 2022 13 June]. Available from: https://fheurope.org/latest-news/post-technical-meeting-statement-on-fh-paediatric-screening/.
Search in Google Scholar Back to article
Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol. 2020; 5(2): 217–29.
Search in Google Scholar Back to article
Sharma S, Khudiwal A, Bhardwaj S, Chaturvedi H, Gupta R. Healthcare worker-based opportunistic screening for familial hypercholesterolemia in a low-resource setting. PLoS One. 2022; 17(6): e0269605. DOI: 10.1371/journal.pone.0269605
Open DOI Search in Google Scholar Back to article
World Heart Federation. Improving prevention and control of raised cholesterol: A Call to Action. Geneva, Switzerland; 2021.
Search in Google Scholar Back to article
Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgözoğlu LS, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022; 43(8): 830–3. DOI: 10.1093/eurheartj/ehab718
Open DOI Search in Google Scholar Back to article
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–337. DOI: 10.1093/eurheartj/ehab484
Open DOI Search in Google Scholar Back to article
Correa VC, Lugo-Agudelo LH, Aguirre-Acevedo DC, Contreras JAP, Borrero AMP, Patiño-Lugo DF, et al. Individual, health system, and contextual barriers and facilitators for the implementation of clinical practice guidelines: A systematic metareview. Health Res Policy Syst. 2020; 18(1): 74. DOI: 10.1186/s12961-020-00588-8
Open DOI Search in Google Scholar Back to article
Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and Strategies in Guideline Implementation-A Scoping Review. Healthcare (Basel). 2016; 4(3). DOI: 10.3390/healthcare4030036
Open DOI Search in Google Scholar Back to article
NCD Alliance. Trans Fat Free by 2023: Case studies in Trans Fat Elimination. Geneva, Switzerland; 2019.
Search in Google Scholar Back to article
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice – Supplementary Data. Eur Heart J. 2021; 42(34): 3227–337. DOI: 10.1093/eurheartj/ehab484
Open DOI Search in Google Scholar Back to article
McCrindle BW, Gidding SS. What Should Be the Screening Strategy for Familial Hypercholesterolemia? N Engl J Med. 2016; 375(17): 1685–6. DOI: 10.1056/NEJMe1611081
Open DOI Search in Google Scholar Back to article
Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018; 72(6): 662–80. DOI: 10.1016/j.jacc.2018.05.044
Open DOI Search in Google Scholar Back to article
Watanabe JH, Kazerooni R, Bounthavong M. Association of copayment with likelihood and level of adherence in new users of statins: A retrospective cohort study. J Manag Care Pharm. 2014; 20(1): 43–50. DOI: 10.18553/jmcp.2014.20.1.43
Open DOI Search in Google Scholar Back to article
Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis. Lancet. 2021; 398(10306): 1133–46. DOI: 10.1016/S0140-6736(21)01827-4
Open DOI Search in Google Scholar Back to article
Huffman MD, Yusuf S. Polypills: Essential medicines for cardiovascular disease secondary prevention? J Am Coll Cardiol. 2014; 63(14): 1368–70. DOI: 10.1016/j.jacc.2013.08.1665
Open DOI Search in Google Scholar Back to article
Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841): 581–90. DOI: 10.1016/S0140-6736(12)60367-5
Open DOI Search in Google Scholar Back to article

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.5334/gh.1154 | Journal eISSN: 2211-8179

Journal RSS Feed

Language: English

Submitted on: Aug 25, 2022

Accepted on: Aug 29, 2022

Published on: Oct 14, 2022

Published by: Ubiquity Press

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

cholesterol,

low-density lipoprotein cholesterol prevention,

ASCVD,

lipid lowering therapy,

familial hypercholesterolaemia

© 2022 Kausik K. Ray, Brian A. Ference, Tania Séverin, Dirk Blom, Stephen J. Nicholls, Mariko H. Shiba, Wael Almahmeed, Rodrigo Alonso, Magdalena Daccord, Marat Ezhov, Rosa Fernández Olmo, Piotr Jankowski, Fernando Lanas, Roopa Mehta, Raman Puri, Nathan D. Wong, David Wood, Dong Zhao, Samuel S. Gidding, Salim S. Virani, Donald Lloyd-Jones, Fausto Pinto, Pablo Perel, Raul D. Santos, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 17 (2022): Issue 1